Organization: Health Canada
Year: 2024
Month: June
Request Number: A-2023-001271
Request Summary: New Drug Submission (NDS) for avapritinib filed by Blueprint Medicines Corporation was accepted into review by Health Canada in or around November 2023. Provide the Product Information Template: Regulatory Enrollment Process (the equivalent of Section #67 of the previous HC/SC-3011 Drug Submission Application Form) for the Avapritinib NDS, setting out the proposed indication/use of the new drug.
Disposition: Disclosed in part
Number of pages: 11